EGFR and non-small cell lung carcinoma: Studies conducted across Asia, encompassing populations from China, Taiwan, and India, have consistently reported that metastatic NSCLC patients with EGFR Exon 20ins mutations show the worst progression-free survival (PFS) and overall survival (OS) when treated with first-generation EGFR TKIs as either first-line or subsequent therapy (5, 6).